...Jorge Di Paola, MD; Stephan Lethagen, MD, PhD; Joan Gill, MD; Pier Mannucci, MD; Jonathan Bernstein, MD; William Nichols, MD; Carl Friedman, MD; Sigurd Knaub, PhD; Garrett Bergman, MD Introduction: Although widely used for the treatment of VWD, optimal doses of VWF/FVIII concentrates for surgical...

...Jeffrey I. Zwicker; Flora Peyvandi; Roberta Palla; Rossana Lombardi; Maria Teresa Canciani; Andrea Cairo; Diego Ardissino; Luisa Bernardinelli; Kenneth A. Bauer; Jack Lawler; Pier Mannucci The N700S polymorphism of thrombospondin-1 (TSP-1) has been identified as a potential genetic risk factor...

...Pier Mannuccio Mannucci; Flora Peyvandi The last 10 years witnessed the publication of many studies on the pathophysiology of thrombotic thrombocytopenic purpura (TTP), a life-threatening disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and multiorgan failure. The most...

...Giuseppe Tagariello; Alfonso Iorio; Elena Santagostino; Massimo Morfini; Ruggero Bisson; Massimo Innocenti; Maria Elisa Mancuso; Maria Gabriella Mazzucconi; Gian Luigi Pasta; Paolo Radossi; Giuseppina Rodorigo; Cristina Santoro; Roberto Sartori; Antonio Scaraggi; Luigi Pier Solimeno; Pier Mannuccio...

...Craig Kessler; Fernando F Corrales-Medina; Pier Mannuccio Mannucci; Michael D Tarantino Introduction: Individualized prophylaxis is the gold standard for treating people with hemophilia A. Healthcare costs are high among patients with severe hemophilia A, because of the need for lifelong...

...Massimo Cugno; Mara Cabibbe; Monica Galli; Pier Luigi Meroni; Sonia Caccia; Rosaria Russo; Bianca Bottasso; Pier Mannuccio Mannucci The causes of thrombosis and pregnancy loss in antiphospholipid syndrome (APS) are still unknown, although several hypotheses have been proposed and hypofibrinolysis...

...Craig Kessler; Fernando F Corrales-Medina; Pier Mannuccio Mannucci; Michael D. Tarantino Background: Personalized factor VIII (FVIII) prophylaxis is currently the gold standard approach for the treatment of patients with severe hemophilia A. Although several FVIII concentrates are available, head...

...Craig Kessler; Fernando F Corrales-Medina; Pier Mannuccio Mannucci; Michael D. Tarantino Background: Personalized prophylaxis with factor VIII (FVIII) concentrates remains the mainstay therapy for patients with severe hemophilia A. The bispecific monoclonal antibody emicizumab, which mimics FVIII...

...Carla Valsecchi; Roberta Gualtierotti; Sara Arcudi; Alessandro Ciavarella; Lucia Schiavone; Cristina Novembrino; Simona Maria Siboni; Pier Mannuccio Mannucci; Flora Peyvandi Data are available on request from the corresponding author, Flora Peyvandi ( [email protected] ). 11 10...

...Carla Valsecchi; Roberta Gualtierotti; Sara Arcudi; Alessandro Ciavarella; Lucia Schiavone; Cristina Novembrino; Simona Maria Siboni; Pier Mannuccio Mannucci; Flora Peyvandi Figure 1 Gualtierotti: Pfiser: Membership on an entity's Board of Directors or advisory committees...

...; Riitta Lassila; Frank W. G. Leebeek; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Renato Marino; Nikolas Nikšić; Florian Oyen; Cristina Santoro; Andreas Tiede; Gholamreza Toogeh; Alberto Tosetto; Marc Trossaert; Eva M. K. Zetterberg; Jeroen Eikenboom; Augusto B. Federici; Flora Peyvandi Type...

...Pier Mannuccio Mannucci The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss...

...Pier Mannuccio Mannucci The management of von Willebrand disease (VWD) is based upon the dual correction of the primary hemostasis defect, due to the inherited deficiency of von Willebrand factor (VWF), and of the secondary defect of factor VIII coagulant activity (FVIII:C), due to the loss...

..., MD; Mathew Thomas, MD; Ezio Zanon; Marilyn J Manco-Johnson, MD; Monica Martinez, MD; Maria Gabriella Mazzucconi, MD; Daniela Neme, MD; Rogelio Alejandro Paredes-Aguilera, MD; Alessandra N L Prezotti, MD MSc; Klaus Schmitt, MD; Bulent Zulfikar, Prof; Pier Mannuccio Mannucci, MD; Frits Richard...

... Richard Morris Hay, MD FRCP, FRCPath; Hamid Hoorfar, MD; Mehran Karimi, MD; Bijan Keikhaei; Riitta Lassila, MD PR; Frank W.G. Leebeek, MD PhD; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci; Maria Gabriella Mazzucconi, MD; Massimo Morfini; Johannes Oldenburg; Ian Peake, PhD; Rafael Parra Lòpez...

...; Peyman Eshghi, MD; Cosimo Ettorre, MD; Jenny Goudemand, MD PhD; Wolf Hassenpflug; Charles Richard Morris Hay, MDFRCP,FRCPath; Hamid Hoorfar, MD; Mehran Karimi, MD; Bijan Keikhaei; Riitta Lassila, MD PR; Frank W.G. Leebeek, MD PhD; Maria Fernanda Lopez Fernandez; Pier Mannuccio Mannucci, MD; Maria...

...Joan Cox Gill, MD; Pier Mannuccio Mannucci; Margaret V. Ragni, MD MPH; Giancarlo Castaman; Flora Peyvandi; Bettina Ploder; Aaron Novack; Peter Chen; Arthur Sytkowski; Bruce Ewenstein Introduction: Recombinant von Willebrand factor (rVWF) has demonstrated hemostatic efficacy and safety when used...

...Frits R. Rosendaal; Roberta Palla; Isabella Garagiola; Pier M. Mannucci; Flora Peyvandi A recent randomized trial, the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET), showed a higher risk of inhibitor development with recombinant factor VIII (rFVIII) than plasma-derived...

...Antonino Cannavò; Carla Valsecchi; Isabella Garagiola; Roberta Palla; Pier Mannuccio Mannucci; Frits R. Rosendaal; Flora Peyvandi The development of anti-factor VIII (FVIII) neutralizing antibodies (inhibitors) is the major complication in hemophilia A. Nonneutralizing antibodies (NNAs) have been...